<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30586">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708537</url>
  </required_header>
  <id_info>
    <org_study_id>1411-BIO-081-MF</org_study_id>
    <nct_id>NCT02708537</nct_id>
  </id_info>
  <brief_title>Effect of Plasma Rich in Growth Factors on Semen Quality</brief_title>
  <official_title>Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Bilbao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bTI Vitoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVI Bilbao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because
      it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy
      rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet growth factors are a group of proteins involved in cellular communication modifying
      biological responses. Obtaining plasma rich in growth factors is already widespread and
      simple protocol technique that is being used in various areas of medicine with superb
      results. Described many of the growth factors present in the PRGF are related to sperm
      parameters, especially motility The described effects have been studied in mammalian and
      each growth factor individually. PRGF contains a pool of growth factors and therefore be
      interesting to analyze their effect on various sperm parameters.

      One of those parameters is very important for fertilization sperm motility, since the lack
      of it will prevent displacement by the cervix to meet the egg in the fallopian tube.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the percentage of motile sperm adding PRGF versus those samples that growth factors were not added</measure>
    <time_frame>6 months</time_frame>
    <description>Within concerted donor visits in IVI Bilbao will be held:
Removing Blood 9 mL of blood to obtain plasma rich in factors growth
Seminogram to analyze all semen parameters according to the criteria of the WHO (2010), paying particular attention to sperm motility.
Sperm vitality will be analyzed before and after treatment with PRGF. PRGF application on the seminal aliquots will be conducted at different concentrations assessing sperm motility.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Vascular Endothelial Growth Factor Overexpression</condition>
  <arm_group>
    <arm_group_label>PRGF in candidates for sperm donors</arm_group_label>
    <description>Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRGF in candidates for sperm donors</intervention_name>
    <description>PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.</description>
    <arm_group_label>PRGF in candidates for sperm donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-35 years

          -  more than 5 million sperm per milliliter

        Exclusion Criteria:

          -  Not having genetic and infectious diseases

          -  Do not suffer mental illness

          -  Have a family study determined that there is no risk of hereditary diseases

          -  There have fathered more than 6 children in the country
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos Ferrando</last_name>
    <role>Study Director</role>
    <affiliation>IVI Bilbao</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Quintana</last_name>
    <phone>+34 944 80 60 20</phone>
    <email>fernando.quintana@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcos Ferrando</last_name>
    <phone>+34 944 806020</phone>
    <email>fernando.quintana@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Bilbao</name>
      <address>
        <city>Leioa</city>
        <state>Vizcaya</state>
        <zip>48011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Matorras</last_name>
    </contact>
    <contact_backup>
      <last_name>Fernando Quintana</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IVI Bilbao</name>
      <address>
        <city>Leioa</city>
        <state>Vizcaya</state>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Quintana</last_name>
      <phone>+34 944806020</phone>
      <phone_ext>20504</phone_ext>
      <email>fernando.quintana@ivi.es</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Ferrando</last_name>
      <phone>+34 944 806020</phone>
      <phone_ext>20503</phone_ext>
      <email>marcos.ferrando@ivi.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>BTI</name>
      <address>
        <city>Vitoria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gorka Orive</last_name>
      <phone>+34 945 160 653</phone>
      <email>gorka.orive@bti-implant.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 9, 2016</lastchanged_date>
  <firstreceived_date>March 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>share data to BTI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
